Lilly: Cut costs without 'sweeping layoffs'

Eli Lilly is scuttling its 2008 profit forecast, citing the costs of buying ImClone Systems. The $6.5 billion acquisition will spawn a charge against earnings of $4.05 to $4.50 a share, which will eat up previously expected earnings of $2.44 to $2.49 a share, leaving a loss of up to $2.06.

But without those charges, Lilly predicts healthy EPS of $3.97 to $4.02. And for 2009, the company is looking for $4.30 to $4.55 in EPS. That's because Lilly is counting on big sales growth again next year, powered by growth in Cymbalta, Alimta, Cialis, and Humalog--and, knock on wood, the launch of its long-awaited anticlotting med prasugrel.

Execs are telling analysts and investors this morning that Lilly plans to continue "fundamentally transforming" its business. That means more cost-cutting, more streamlining and more pipeline work. That might sound scary to Lilly employees--except for the fact that the company says it has no plans to make sweeping layoffs.

- see the MarketWatch story
- read the column at the Indianapolis Star

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.